Source:http://linkedlifedata.com/resource/pubmed/id/14650958
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2003-12-3
|
pubmed:abstractText |
The development of various kinds of autoimmune disease as a result of interferon-alpha (IFN-alpha) therapy has been reported among chronic myeloproliferative disorders(CMPD) including chronic myeloid leukemia(CML). Therefore, we investigated the frequency of autoimmune disorders in 33 patients with hematopoietic diseases treated with IFN-alpha in our department. Thirty-three patients (12 females, 21 males) included cases of CML (n = 23), essential thrombocythemia (ET) (n = 1), multiple myeloma (n = 8), and hypereosinophilic syndrome (HES) (n = 1). Autoantibodies (ANA, dsDNA, and RAPA), thyroid grand functions, and coagulant functions were examined. Twenty-five out of 33 patients were treated with natural IFN-alpha, and 8 patients were treated with recombinant IFN-alpha 2b (rIFN alpha-2b). Three patients were treated with IFN and anticancer agents. Antinuclear antibodies were detected in 2 of 33 patients. RAPA and anti-thyroglobulin antibody became positive in 3 and 4 patients, respectively. Ten patients showed low serum levels of either free T3 and/or free T4. However, none of them showed any clinical symptoms for developing autoimmune diseases. In addition, circulating anticoagulant antibodies were detected in 3 of 23 patients with CML treated with rIFN alpha-2b, but in no cases treated with natural IFN-alpha. Although none of the patients developed autoimmune diseases, we concluded that patients receiving IFN therapy should be carefully monitored for clinical signs and symptoms of autoimmune disorders.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0385-0684
|
pubmed:author |
pubmed-author:IguchiTomotakaT,
pubmed-author:ItoYoshikazuY,
pubmed-author:IwaseOsamuO,
pubmed-author:KawakuboKenK,
pubmed-author:KimuraYukihikoY,
pubmed-author:KuriyamaYuzuruY,
pubmed-author:MiyazawaKeisukeK,
pubmed-author:NishimakiJirohJ,
pubmed-author:OhyashikiKazumaK,
pubmed-author:ShimamotoTakashiT,
pubmed-author:SuzukiAkitakaA,
pubmed-author:TauchiTetsuzoT,
pubmed-author:YaguchiMakotoM
|
pubmed:issnType |
Print
|
pubmed:volume |
30
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1911-6
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:14650958-Adult,
pubmed-meshheading:14650958-Aged,
pubmed-meshheading:14650958-Antineoplastic Agents,
pubmed-meshheading:14650958-Autoimmune Diseases,
pubmed-meshheading:14650958-Female,
pubmed-meshheading:14650958-Humans,
pubmed-meshheading:14650958-Interferon-alpha,
pubmed-meshheading:14650958-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:14650958-Male,
pubmed-meshheading:14650958-Middle Aged,
pubmed-meshheading:14650958-Myeloproliferative Disorders,
pubmed-meshheading:14650958-Recombinant Proteins
|
pubmed:year |
2003
|
pubmed:articleTitle |
[Autoimmune phenomena during interferon-alpha therapy for hematopoietic disorders].
|
pubmed:affiliation |
First Dept. of Internal Medicine, Tokyo Medical University.
|
pubmed:publicationType |
Journal Article,
English Abstract,
Case Reports
|